References
- Bangsberg, D. R., Charlebois, E. D., Grant, R. M., Holodniy, M., Deeks, S. G., Perry, S., Conroy, K. N., Clark, R., Guzman, D., Zolopa, A., & Zolopa, A. (2003). High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS, 17(13), 1925–1932. https://doi.org/10.1097/00002030-200309050-00011
- Bhattacharya, J., Goldman, D., & Sood, N. (2003). The link between public and private insurance and HIV-related mortality. Journal of Health Economics, 22(6), 1105–1122. https://doi.org/10.1016/j.jhealeco.2003.07.001
- Cohen, M. S., Chen, Y. Q., McCauley, M., Gamble, T., Hosseinipour, M. C., Kumarasamy, N., Hakim, J. G., Kumwenda, J., Grinsztejn, B., Pilotto, J. H., & Pilotto, J. H. (2011). Prevention of HIV-1 infection with early antiretroviral therapy. New England Journal of Medicine, 365(6), 493–505. https://doi.org/10.1056/NEJMoa1105243
- Gagnon, M. (2014). Rethinking HIV-related stigma in health care settings: A research brief. University of Ottawa.
- Gardner, E. M., McLees, M. P., Steiner, J. F., del Rio, C., & Burman, W. J. (2011). The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clinical Infectious Diseases, 52(6), 793–800. https://doi.org/10.1093/cid/ciq243
- Gorman, C., Rachlis, B., Light, L., Burchell, A., Yoong, D., Antoniou, T., & Kroch, A. (2019, May 13–15). Epidemiology and Biostatistics at the Nexus of Complex Health Challenges. The impact of drug coverage on paying for antiretroviral medications: Results from the Ontario HIV treatment network cohort study [Paper presentation]. Canadian Society of Epidemiology and Biostatistics Biennial National Conference, Ottawa, ON.
- Haddad, N., Li, J., Totten, S., & McGuire, M. (2018). Adult immunization: HIV in Canada – surveillance report, 2017. Canada Communicable Disease Report, 44(12). 348. https://doi.org/10.14745/ccdr.v44i12a03
- Horstmann, E., Brown, J., Islam, F., Buck, J., & Agins, B. D. (2010). Retaining HIV-infected patients in care: Where are we? Where do we go from here? Clinical Infectious Diseases, 50(5), 752–761. https://doi.org/10.1086/649933
- Iacob, S. A., Iacob, D. G., & Jugulete, G. (2017). Improving the adherence to antiretroviral therapy, a difficult but essential task for a successful HIV treatment-clinical points of view and practical considerations. Frontiers in Pharmacology, 8, 831. https://doi.org/10.3389/fphar.2017.00831
- Johnston, S. S., Juday, T., Seekins, D., Espindle, D., & Chu, B.-C. (2012). Association between prescription cost sharing and adherence to initial combination antiretroviral therapy in commercially insured antiretroviral-naïve patients with HIV. Journal of Managed Care Pharmacy, 18(2), 129–145. https://doi.org/10.18553/jmcp.2012.18.2.129
- Kane, M., & Trochim, W. M. (2007). Concept mapping for planning and evaluation (Vol. 50). Sage.
- Law, M. R., Cheng, L., Dhalla, I. A., Heard, D., & Morgan, S. G. (2012). The effect of cost on adherence to prescription medications in Canada. Canadian Medical Association Journal, 184(3), 297–302. https://doi.org/10.1503/cmaj.111270
- Madden, J. M., Graves, A. J., Zhang, F., Adams, A. S., Briesacher, B. A., Ross-Degnan, D., & Soumerai, S. B. (2008). Cost-related medication nonadherence and spending on basic needs following implementation of Medicare part D. Journal of the American Medical Association, 299(16), 1922–1928. https://doi.org/10.1001/jama.299.16.1922
- Mill, J., Edwards, N., Jackson, R., Austin, W., MacLean, L., & Reintjes, F. (2009). Accessing health services while living with HIV: Intersections of stigma. Canadian Journal of Nursing Research, 41(3), 168–185.
- Ohl, M., Dillon, D., Moeckli, J., Ono, S., Waterbury, N., Sissel, J., Yin, J., Neil, B., Wakefield, B., & Kaboli, P. (2013). Mixed-methods evaluation of a telehealth collaborative care program for persons with HIV infection in a rural setting. Journal of General Internal Medicine, 28(9), 1165–1173. https://doi.org/10.1007/s11606-013-2385-5
- Ontario Ministry of Health and Long Term Care. (n.d.). Ontario drug benefit formulary. Retrieved November 18, 2019, from https://www.formulary.health.gov.on.ca/formulary/
- Public Health Agency of Canada. (2015, December 1). HIV and AIDS in Canada: Surveillance report to December 31, 2014. https://www.canada.ca/en/public-health/services/publications/diseases-conditions/hiv-aids-canada-surveillance-report-december-31-2014.html
- Rachlis, B., Light, L., Gardner, S., Burchell, A. N., Raboud, J., Kendall, C., McIsaac, M. A., Murray, J., Rachlis, A., & Rourke, S. B. (2018). The impact of drug coverage on viral suppression among people living with HIV in Ontario, Canada. Canadian Journal of Public Health, 109(5–6), 800–809. https://doi.org/10.17269/s41997-018-0104-z
- Rachlis, B., Light, L., Kopansky-Giles, M., Nam, S, Burchell, A, Antoniou, T, Yoong, D, Cooper, C, Kendall, C, Loutfy, M, Rachlis, A, Silverman, M, Salit, I, & Kroch, A. (2018). Challenges with affording HIV medications among participants in the Ontario HIV treatment network cohort study [Poster presentation]. 27th annual conference on HIV/AIDS research, Vancouver, BC.
- Yoong, D., Bayoumi, A. M., Robinson, L., Rachlis, B., & Antoniou, T. (2018). Public prescription drug plan coverage for antiretrovirals and the potential cost to people living with HIV in Canada: A descriptive study. Canadian Medical Association Journal Open, 6(4), E551. https://doi.org/10.9778/cmajo.20180058